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ABSTRACT
Objectives: To estimate the ‘real-world effectiveness
of statins for primary prevention of cardiovascular
disease (CVD) and for lipid modification in people with
severe mental illnesses (SMI), including schizophrenia
and bipolar disorder.
Design: Series of staggered cohorts. We estimated the
effect of statin prescribing on CVD outcomes using a
multivariable Poisson regression model or linear
regression for cholesterol outcomes.
Setting: 587 general practice (GP) surgeries across
the UK reporting data to The Health Improvement
Network.
Participants: All permanently registered GP patients
aged 40–84 years between 2002 and 2012 who had a
diagnosis of SMI. Exclusion criteria were pre-existing
CVD, statin-contraindicating conditions or a statin
prescription within the 24 months prior to the study start.
Exposure: One or more statin prescriptions during a
24-month ‘baseline’ period (vs no statin prescription
during the same period).
Main outcome measures: The primary outcome
was combined first myocardial infarction and stroke.
All-cause mortality and total cholesterol concentration
were secondary outcomes.
Results: We identified 2944 statin users and 42 886
statin non-users across the staggered cohorts. Statin
prescribing was not associated with significant
reduction in CVD events (incident rate ratio 0.89; 95%
CI 0.68 to 1.15) or all-cause mortality (0.89; 95% CI
0.78 to 1.02). Statin prescribing was, however,
associated with statistically significant reductions in
total cholesterol of 1.2 mmol/L (95% CI 1.1 to 1.3) for
up to 2 years after adjusting for differences in baseline
characteristics. On average, total cholesterol decreased
from 6.3 to 4.6 in statin users and 5.4 to 5.3 mmol/L
in non-users.
Conclusions: We found that statin prescribing to
people with SMI in UK primary care was effective for
lipid modification but not CVD events. The latter
finding may reflect insufficient power to detect a
smaller effect size than that observed in randomised
controlled trials of statins in people without SMI.
INTRODUCTION
People with severe mental illness (SMI)
including schizophrenia and bipolar disorder
are at a twofold to threefold higher risk of
cardiovascular disease (CVD) than compar-
able individuals without SMI.1 2 CVD drives a
substantial portion of the 13–30 years deﬁcit
in life expectancy relative to the general
population3 and National Institute for
Health and Care Excellence (NICE) guide-
lines identify people with SMI as a popula-
tion for which statin prescribing should be
considered.4–6 Statins are cost-effective for
preventing CVD events within randomised
controlled trial (RCT) populations without
mental illness.7 However, we do not know
whether statins are similarly effective in
people with SMI, since this population has
differences in CVD risk proﬁle (such as
very high rates of smoking, obesity and
diabetes). Furthermore, people with SMI
may adhere to medication differently and
have additional exposure to antipsychotic
Strengths and limitations of this study
▪ We used a large and representative data source
that records real-world clinical data on cardiovas-
cular outcomes and lipid modification in people
with severe mental illness.
▪ Such data are both costly and difficult to obtain
from other data sources and recruitment of
people with severe mental illness into clinical
trials may be challenging and result in substan-
tial selection bias.
▪ We applied specialist methods to reduce the
impact of confounding by indication (staggered
cohort and multivariable regression) and handle
missing covariate data (multiple imputation)
within our study.
▪ However, these methods can only reduce bias
arising from differences in measured confoun-
ders. Residual confounding may remain due to
unmeasured confounders such as diet or sever-
ity of mental illness.
▪ We were not able to examine the association
between statin prescribing and lipid modification
among people who had missing data on total
cholesterol at baseline.
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medications, which are associated with increased risk
of dyslipidaemia.
We do not know if results from existing RCTs can be
extrapolated to real-world impacts of statin prescribing
to people with SMI. Over two-thirds of the participants
in the most recent meta-analysis of statins for primary
prevention of CVD7 were derived from studies that
explicitly excluded participants with psychological condi-
tions (50%; n=28 390)8–10 or individuals who were per-
ceived as less likely to be compliant with treatment
(20%; n=10 797).11–13
Few studies have assessed statin medication adherence
in people with SMI and we are unaware of any that
focus exclusively on primary CVD prevention. However,
a small number of important studies have investigated
cardiovascular medication adherence for combined
primary and secondary prevention and report compar-
able or better adherence for people with schizophrenia
relative to controls.14 15 Despite such ﬁndings, mental
illness is sometimes perceived as a barrier to good medi-
cation adherence16–18 and might therefore deter
general practitioners from prescribing statins to people
with SMI.19 Indeed, signiﬁcant inequalities in statin pre-
scribing have been reported for people with SMI.20 In
addition, in vitro studies indicate that some antipsychotic
agents interact with transcription factors for enzymes
involved in cholesterol and fatty acid synthesis (includ-
ing 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)
reductase, the primary binding site for statins) and
could therefore counteract the cholesterol-lowering
action of statins.21 22 The degree of interaction appears
to vary by type of antipsychotic and is more strongly cor-
related with agents such as clozapine, which are asso-
ciated with weight gain.23 24
We aimed to estimate the real-world impact of statin pre-
scribing on people with SMI by comparing people with
SMI who did (statin users), or did not (statin non-users),
receive a statin prescription. We estimated the effect of
statin prescribing on:
1. Combined ﬁrst myocardial infarction (MI) and stroke
(primary outcome);
2. All-cause mortality;
3. Change in total cholesterol concentration at 1 and
2 years after initiating a statin.
METHODS
Study design
We used data from The Health Improvement Network
(THIN), which captures anonymised data from elec-
tronic health records from over 12 million patients regis-
tered at 587 general practice (GP) surgeries (∼5.7% of
the UK population).25 See end of article for details of
ethical approval. This data source has been used exten-
sively to investigate CVD risk in people with SMI.1 26 27
Individuals with SMI routinely access primary care28 and
the validity of SMI diagnoses in computer records has
been established.29 Furthermore, the incidence of SMI
has been found to be comparable to other
epidemiological studies.30 THIN data are recorded as
hierarchical medical codes (Read codes), free-text com-
ments, drug codes for prescribed medications, referrals
and additional health information such as laboratory
test results.31 32 The Townsend score for the quintile of
deprivation for a patient’s address reﬂects deprivation
(employment, household occupancy, car and home own-
ership as recorded in the 2001 census) at enumeration
district level, which covers areas of ∼150 households.33
Classiﬁcation criteria (including case deﬁnitions for
SMI, CVD and statin prescribing) for this study are out-
lined in online supplementary ﬁle S1 and code lists are
available on request from the authors. We included all
people with a diagnosis of schizophrenia or bipolar dis-
order who were aged 40–84 years and consulted their
GP between 1 January 2002 and 31 December 2013. We
excluded patients who were not permanently registered,
and data for time periods before the practice acceptable
mortality rate, acceptable computer usage dates34 35 and
for the 12 months after patient registration.36 We
excluded individuals who—before the cohort start—had
any of: CVD diagnosis, statin prescription in the prior
24 months, condition likely to impact on initiating a statin
(terminal illness, dementia or raised alanine transaminase
and aspartate transaminase; deﬁned as >3x upper limit of
normal range; 124 and 116 IU/L, respectively).
As described more fully in our study protocol (see
online supplementary ﬁle S2), we used a staggered
cohort study design to reduce the impact of confound-
ing by indication.37 This type of study design has success-
fully been applied to other studies comparing an active
(including statins for primary CVD) and passive treat-
ment groups.38–40
We used THIN data to create ﬁve ‘staggered’ cohort
studies with 2-year follow-up periods between 1 January
2002 and 1 January 2010 (ﬁgure 1). Further detail
regarding the selection of the time window is outlined in
online supplementary ﬁle S3. We assessed the effective-
ness of statin prescribing using pooled data from these
cohorts. Each cohort study compared statin user and non-
statin user comparator groups, which were deﬁned by
whether or not an individual was prescribed a statin (one
or more prescriptions) during the ﬁrst 24 months of the
study start. Statin users and non-users were redeﬁned at
the start of each separate staggered cohort.
Figure 1 Diagrammatic representation of the staggered
cohort study design.
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Statin users began follow-up on the day of their ﬁrst
statin prescription (the index date); for non-statin users,
the index date was a randomly selected day within the
2-year exposure period. Statin users and non-users who
had a CVD event recorded within 3 months of the index
date were excluded because this pattern may reﬂect
delayed recording of the CVD event, where the statin was
initiated for secondary prevention of CVD. The end of
follow-up was ﬁrst CVD event, death or loss to follow-up
(out of practice transfer or end of the study period).
The primary outcome was ﬁrst MI or stroke (com-
bined MI, haemorrhagic and ischaemic or unspeciﬁed
stroke). Secondary outcomes were all-cause mortality,
MI, stroke, change in total cholesterol level/concentra-
tion (for those with available records) 1 and 2 years
after the index date. We selected these outcomes
because other studies have identiﬁed high positive pre-
dictive values (85–95% for CVD events and 99% for all-
cause mortality) for MI,41 42 stroke43 44 and all-cause
mortality45 in THIN and closely related databases. We
also considered investigating coronary heart disease
(CHD) as an outcome, but feasibility work suggested
that some CHD Read codes such as ‘unspeciﬁed CHD’
may reﬂect retrospective recording of pre-existing CHD.
We extracted data on covariates recorded during
the 12 months before the index date (see online
supplementary ﬁles S1 and S3). Covariates included age,
sex, type of SMI, blood pressure, weight, height, choles-
terol concentration, diabetes, smoking status, Townsend
score, antihypertensive use, non-statin lipid modiﬁcation
(eg, ﬁbrates), heavy alcohol drinking, familial hyperchol-
esterolaemia, hypothyroidism, chronic kidney disease,
chronic obstructive pulmonary disease, asthma, atrial ﬁb-
rillation, predominant antipsychotic, mood stabilising
drug, antidepressant drug, annual consultation rate and
cancer diagnosis.
Unobserved covariate data (total cholesterol, height,
weight, systolic blood pressure and smoking status) were
estimated for the full study population using multiple
imputation with chained equations to generate 10 imputed
data sets.46 Data were separately imputed by gender in
each of the ﬁve cohorts and used covariate data measured
within 3 years of baseline. CVD events and Nelson-Aalen
estimates of the cumulative hazard function for the time to
event were included in the imputation model.47 A detailed
description of the model and subsequent data checks is
outlined in online supplementary ﬁle S3.
Analysis
Data for each of the ﬁve cohort studies were pooled to
obtain average estimates for the whole study period.
Incident rate ratios (IRRs) for the association between
statin prescribing and combined MI and stroke were esti-
mated using a Poisson regression model with receipt of
a statin prescription as the exposure and ﬁrst MI or
stroke event as the outcome: the log of follow-up time
was used as an offset. Since the same individual could
be included in more than one cohort, the ‘robust
sandwich estimator’ was used to calculate conservative
estimates of variance.48 The model was adjusted for cov-
ariates outlined previously. We also assessed the impact
of log-transforming continuous variables and including
interaction terms for age and sex.
All analyses were undertaken using an intention-
to-treat approach with exposure deﬁned by statin pre-
scribing at the index date. The primary analysis was
repeated for: all-cause mortality (death from any cause),
ﬁrst stroke (haemorrhagic or ischaemic stroke) and ﬁrst
MI to identify whether the effectiveness of statins was
substantially altered for each of these outcomes.
Changes in total cholesterol concentration measured
during the 1 and 2 years after the index date (ie, 1–365
or 366–730 days after the index date, respectively) were
evaluated for statin users and non-users in individuals
with complete data at baseline. For this analysis, linear
regression models with total cholesterol at 1 or 2 years
after the index date were developed using the same
array of covariates as for the main analysis. Change in
cholesterol as an outcome for individuals who did not
have complete data was not assessed. Data management
and analysis were undertaken in Stata V.14.
RESULTS
Overall, 45 830 participants (deﬁned as total statin users
and non-users under follow-up) were included in the
pooled data set. These participants reﬂect data for
16 854 individuals with schizophrenia or bipolar dis-
order who, on average, were included in 2.7 of the ﬁve
possible cohorts. A total of 25 statin users and 27 non-
statin users were excluded because they had a CVD
event recorded within 3 months of the index date. A
ﬂow chart outlining numbers of statin users and
non-users in and the associated event rate for each of
the ﬁve cohort studies is outlined in ﬁgure 2. Table 1
describes the baseline characteristics of statin users and
non-users for the full study population (using imputed
data) compared with the subset with fully observed cov-
ariate data at baseline. Of note, total cholesterol concen-
tration at baseline differed in statin users and non-users.
The distribution of estimated CVD risk scores was differ-
ent for statin users and non-users, with baseline risk
being higher (on average) for statin users. Statin users
also had greater levels of deprivation, consulted more
frequently and had higher frequencies of prescribing—
including antihypertensives and antidepressants—and to
have familial hypercholesterolaemia (for which statin
therapy is indicated; table 1).
Modelled associations between covariates and statin
prescribing or CVD events are outlined in the
supplementary material for complete cases (see online
supplementary ﬁle 4, table S1) and the imputed data set
(see online supplementary ﬁle 4, table S2).
The outputs of each of the regression models outlined
in the results are included as a supplementary ﬁle (see
online supplementary ﬁle 4).
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The crude rate of ﬁrst MI and stroke per 1000 person-
years of follow-up was 5.74 (95% CI 4.62 to 7.11) in
statin users and 4.17 (95% CI 3.91 to 4.45) in statin
non-users in the full population (further outlined in
ﬁgure 2). The crude IRR for the association between
statin prescribing and MI and stroke events was 1.39
(95% CI 1.11 to 1.74) for the full study population:
which was reduced to 0.89 (95% CI 0.68 to 1.15) after
adjustment for all additional covariates (see online
supplementary ﬁle 4, table S3). Inclusion of quadratic or
log-transformed versions of continuous variables (age,
total cholesterol, systolic blood pressure, body mass
index) in the model did not have a marked impact on
the results (data not shown).
The crude IRR for the association between statin pre-
scribing and all-cause mortality was 1.02 (95% CI 0.90 to
1.14) and was reduced to 0.89 (95% CI 0.78 to 1.02)
after adjusting for all covariates as above (see online
supplementary ﬁle 4, table S3).
The crude IRR for the association between statin pre-
scribing and ﬁrst MI was 1.51 (95% CI 1.04 to 2.18) and
was reduced to 0.75 (95% CI 0.48 to 1.15) after adjust-
ing for all covariates (see online supplementary ﬁle 4,
table S3).
The crude IRR for the association between statin pre-
scribing and ﬁrst stroke was 1.31 (95% CI 0.99 to 1.74)
and was reduced to 0.96 (95% CI 0.68 to 1.15) after
adjusting for all covariates (see online supplementary
ﬁle 4, table S3).
A total of 82% and 73% of the 1714 statin users had
measurements of total cholesterol recorded within the 1
and 2 years after the index date, respectively. By com-
parison, 55% and 57% of statin non-users had a
measurement of cholesterol recorded within the 1 and
2 years after the index date, respectively.
In statin users, total cholesterol decreased on average
by 1.7 mmol/L (27%) from baseline concentrations of
6.3–4.6 mmol/L at both 1 and 2 years after baseline
(table 2). In contrast, among statin non-users, mean
total cholesterol in each individual was slightly decreased
by 0.1 mmol/L (2%) from baseline concentrations of
5.4–5.3 mmol/L at both 1 and 2 years after baseline
(table 2).
The adjusted linear regression model showed a mean
reduction in total cholesterol among statin users (rela-
tive to non-users) of 1.3 mmol/L (95% CI 1.2 to 1.4; see
online supplementary ﬁle 4, table S4) and 1.2 mmol/L
(95% CI 1.1 to 1.3; see online supplementary ﬁle 4,
table S5) at 1 and 2 years after the index date, respect-
ively. Although statin use was the most important pre-
dictor of change in cholesterol concentration at both
time points, baseline cholesterol was also strongly asso-
ciated with subsequent changes in total cholesterol
(coefﬁcients of −0.36 and −0.41 at 1 and 2 years,
respectively; see online supplementary ﬁle 4, tables S4
and S5, respectively).
DISCUSSION
Principal findings
Our results provide evidence that statin prescribing to
people with SMI may carry a similar level of beneﬁt to
the general population with observed reductions for
total cholesterol of 1.2 mmol/L for up to 2 years. While
non-signiﬁcant, the effect estimates for combined MI
and stroke (IRR 0.89; 95% CI 0.68 to 1.15) and all-cause
Figure 2 Flow chart of statin users and non-users contributing data to each of the five cohorts in the full population. MI,
myocardial infarction.
4 Blackburn R, et al. BMJ Open 2017;7:e013154. doi:10.1136/bmjopen-2016-013154
Open Access
Table 1 Characteristics of the study population at baseline (for complete records and the full population after imputation of unobserved data)
Characteristic at baseline
Complete cases Full population
Statin non-user IQR [or %] Statin user IQR [or %] Statin non-user IQR [or %] Statin user IQR [or %]
Total participants under follow-up* 5201 1714 42 886 2944
Bipolar 2612 [50%] 835 [49%] 21 883 [51%] 1460 [50%]
Median age (years) 55 (48, 64) 58 (50, 65) 54 (47, 64) 59 (51, 67)
Male 2438 [47%] 866 [51%] 19 191 [45%] 1400 [48%]
Diabetes (yes) 1156 [22%] 943 [55%] 3393 [8%] 1020 [35%]
Median systolic BP (mm Hg)† 131 (120, 141) 136 (125, 147) 130 (120, 141) 137 (126, 148)
Per cent imputed [43%] [7%]
Median BMI† 28 (25, 33) 30 (26, 34) 27 (24, 31) 30 (26, 34)
Per cent imputed [62%] [30%]
Median cholesterol concentration (mmol/L)† 5.3 (4.7, 6.0) 6.2 (5.5, 7.1) 5.4 (4.8, 6.2) 6.4 (5.6, 7.2)
Per cent imputed [77%] [10%]
Smoker† 3004 [58%] 1120 [65%] 23 486 [55%] 1786 [61%]
Per cent imputed [1%] [0.1%]
Median Framingham CVD risk score (BMI)
Women
40–49 years 6 (4, 10) 10 (7, 16) 5 (4, 7) 10 (6, 14)
50–59 years 11 (8, 15) 19 (12, 26) 10 (7, 14) 17 (11, 24)
60–74 years 20 (13, 30) 29 (19, 42) 17 (12, 25) 25 (17, 38)
75–84 years‡ 34 (23, 49) 36 (27, 56) 26 (18, 36) 34 (24, 48)
Men
40–49 years 14 (10, 20) 20 (15, 28) 12 (9, 16) 19 (14, 26)
50–59 years 26 (18, 35) 33 (2342) 22 (16, 30) 32 (2241)
60–74 years 41 (29, 55) 47 (35, 59) 36 (26, 47) 45 (34, 57)
75–84 years‡ 58 (45, 71) 62 (48, 80) 49 (39, 63) 58 (48, 79)
Characteristic at baseline
Complete cases Full population
Statin non-user Per cent Statin user Per cent Statin non-user Per cent Statin user Per cent
Total participants under follow-up* 5201 1714 42 886 2944
Number of GP consultations during baseline
<4 630 12% 150 9% 10 906 25% 322 11%
4–6 1024 20% 323 19% 9310 22% 568 19%
7–12 1679 32% 561 33% 11 506 27% 942 32%
>12 1868 36% 680 40% 11 158 26% 1112 38%
Antipsychotic use
None 1926 37% 649 38% 20 061 47% 1178 40%
First generation 1091 21% 384 22% 8932 21% 630 21%
Second generation 2184 42% 681 40% 13 886 32% 1136 39%
Townsend score quintile
1 (least deprived) 813 16% 238 14% 7280 17% 448 15%
2 823 16% 253 15% 7419 17% 462 16%
3 987 19% 336 20% 8653 20% 595 20%
Continued
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Table 1 Continued
Characteristic at baseline
Complete cases Full population
Statin non-user Per cent Statin user Per cent Statin non-user Per cent Statin user Per cent
4 1278 25% 380 22% 9731 23% 626 21%
5 (most deprived) 1214 23% 469 27% 9101 21% 755 26%
Not recorded 86 2% 38 2% 969 2% 58 2%
Year of cohort
2002 268 5% 98 6% 7752 18% 285 10%
2004 592 11% 336 20% 8718 20% 605 21%
2006 1024 20% 453 26% 8901 21% 747 25%
2008 1387 27% 427 25% 8994 21% 697 24%
2010 1930 37% 400 23% 8521 20% 610 21%
Total participants under follow-up* 5201 1714 42 886 2944
Antihypertensive use (yes) 1201 23% 1065 62% 5685 13% 961 33%
Antidepressant use (yes) 2156 41% 801 47% 17 252 40% 1371 47%
Mood stabiliser use (yes) 1815 35% 538 31% 13 166 31% 922 31%
Asthma (yes) 596 11% 211 12% 4387 10% 336 11%
COPD (yes) 224 4% 85 5% 1300 3% 132 4%
Familial hypercholesterolaemia (yes) 38 0.7% 173 10% 77 0.2% 302 10%
Atrial fibrillation (yes) 59 1.0% 16 0.9% 406 1.0% 41 1.4%
Cancer diagnosis in past year (yes) 80 2% 22 1.3% 607 1.4% 39 1.3%
Hypothyroidism (yes) 47 0.9% 21 1.2% 342 0.8% 34 1.2%
Chronic kidney disease (yes) 424 8% 102 6% 1398 3% 188 6%
Heavy drinker (yes) 933 18% 293 17% 5994 14% 469 16%
Non-statin lipid modification§ (yes) 66 1.3% 34 2% 196 0.5% 51 2%
*Total participants under follow-up describes the number of statin users and non-users who were included in the pooled data sets derived from combining cohorts from different time periods.
†Denotes variables where unobserved baseline values were imputed in the full population data set.
‡Framingham risk score not validated for individuals aged >74 years.
§Refers to lipid-modifying drugs that are not statins, for example, fibrates.
BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; GP, general practice.
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mortality (0.89 with 95% CI 0.78 to 1.02; ﬁgure 3) were
broadly similar to published estimates from RCT
meta-analysis7 and an externally validated observational
study of people without SMI.49
Comparison with other studies
An IRR of 0.89 (with 95% CI 0.68 to 1.15) is compatible
with rates of MI and stroke being 11% lower among
statin users than non-users within the study sample, but
which—through chance alone—might not translate into
a decreased event rate in the population. Thus, although
the point estimates for our study are similar to observa-
tional studies of statins in the general population,49 50
we cannot conclude that statins are effective in prevent-
ing CVD events in people with SMI. Sample size estima-
tion for this type of study design is not straightforward:
however, Poisson counting error (see online
supplementary ﬁle S5 for more detail) provides an indi-
cation that our study was likely to be adequately powered
to detect a reduction in the rate of MI and stroke with a
magnitude of effect similar to that observed in statin
RCTs (22% reduction)—but not observational studies
(14% reduction)—in people without SMI.7 The esti-
mated association between statin prescribing and all-
cause mortality (IRR of 0.89) was also similar to those
derived from RCT meta-analysis7 and observational
studies,49 although scope for direct comparison is
limited by marked variations in mortality rate and dur-
ation of follow-up between our study and RCTs included
in the meta-analysis.7
Statin use was associated with a mean decrease in total
cholesterol concentration at 1 and 2 years after the
index date of 1.3 and 1.2 mmol/L, respectively (equiva-
lent to a 20–21% decrease from the index date), after
adjusting for differences in the baseline characteristics
of statin users and non-users. RCTs with a minimum of
6 months of follow-up in people without SMI have iden-
tiﬁed a similar net decrease in total cholesterol of
1.05 mmol/L (95% CI 0.76 to 1.35), with variation
between difference types and dosage of statin.7 Two
other studies (that included a control group) have inves-
tigated statin prescribing in people with SMI.51 52 A non-
randomised study compared changes in lipid levels
during a 12-week period in 52 individuals taking 10 mg
rosuvastatin daily and 48 individuals not taking statins:
total cholesterol concentration was decreased by an add-
itional 2.9 mmol/L (35%) in statin users.51 A pilot study
randomised 60 individuals to receive 40 mg pravastatin
daily or no statin for 12 weeks and reported smaller
decreases in total cholesterol of 0.5 mmol/L (11%) in
statin use. This pilot study also examined changes in
cholesterol at 6 weeks after baseline and established that
the reduction in total cholesterol was greater at 6 weeks
than 12 weeks, which may indicate issues with the long-
term effectiveness and/or adherence to statins.52
Strengths and weaknesses
The cholesterol reduction observed in our study lies at
approximately the mid-point between the two published
studies outlined above, which examined rosuvastatin and
pravastatin (10 and 40 mg daily dosage, respectively).
This result is consistent with estimates of the cholesterol-
lowering activity of statins in the general population,
which suggest that 20–40 mg simvastatin (the most com-
monly prescribed statin in our study) has an intermedi-
ate level of activity relative to10 mg rosuvastatin and
40 mg pravastatin.53 Importantly, our results provide the
ﬁrst evidence that cholesterol concentration is reduced
by over 1 mmol/L for up to 2 years, which suggests
that medication adherence is sustained. This ﬁnding is
important because it suggests—in agreement with other
studies54 55—that statin use can result in substantial
reductions in cholesterol among populations with high
antipsychotic usage. Furthermore, other studies in the
Table 2 Summary statistics for change in total cholesterol within 1 and 2 years of the index date
Group Description of metric Baseline 1 year 2 years
Statin non-users Number under follow-up 5201 2865 3002
Mean cholesterol concentration mmol/L (SD) 5.4 (1.0) 5.3 (1.0) 5.3 (1.0)
Change from baseline mmol/L (%) – −0.1 (−2%) −0.1 (−2%)
Statin users Number under follow-up 1714 1409 1253
Mean cholesterol concentration mmol/L (SD) 6.3 (1.2) 4.6 (1.0) 4.6 (1.1)
Change from baseline mmol/L (%) – −1.7 (−27%) −1.7 (−27%)
Figure 3 Key results for the association between statin
prescribing and the rate of MI, stroke and all-cause mortality.
IRR, incident rate ratio; MI, myocardial infarction.
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general population have shown that the impact of statin
prescribing on CVD events increases with extended use:
reductions of 0.6 mmol/L of total cholesterol are asso-
ciated with a 7% decrease in ischaemic heart disease
during the ﬁrst 2 years of therapy and >20% decreases
thereafter.56 The decreased total cholesterol concentra-
tions attributed to statin therapy in people with SMI may
therefore translate into long-term clinically meaningful
reductions in CVD.
A limitation of our study ﬁndings for total cholesterol
is that these apply only to individuals who had complete
data at baseline and who had one or more measure-
ments of total cholesterol recorded in the 2 years after
the index date. Although the ascertainment of choles-
terol outcome data was good for statin users (73–82%),
it is possible that individuals who are more compliant
may be more likely to have a blood test. Therefore, our
results may overestimate the potential effect of initiation
of statin treatment. In addition, outcome data were less
available for statin non-users (55–57%). This is poten-
tially important because, while many trials of statins
suggest that cholesterol concentration is unlikely to
change substantially in the control arm, long-term tem-
poral trends in dyslipidaemia have been observed, even
among those without treatment for lipid modiﬁcation.57
The use of observational data for studies that compare
treated and untreated arms is likely to result in compari-
son groups that differ, especially in terms of their risk
for the condition being medicated. Although this study
employed strategies to increase the comparability of
statin user and non-user groups, the proﬁles of statin
users and non-users differed at baseline, with statin users
having greater CVD risk and a raised crude MI and
stroke event rate. These baseline differences were antici-
pated and—as with other studies38 40 50—addressed
through use of staggered cohort design and adjustment
for known confounders of the association between pre-
scribing and CVD outcomes. The impact of these statis-
tical adjustments was large and reversed the direction of
association between statin prescribing and CVD events,
thus highlighting the importance of confounding and
the extent to which it may be controlled. However, this
approach can only reduce bias arising from differences
in measured confounders. Residual confounding arising
both from time-varying changes in measured covariates
(such as blood pressure within the baseline period) and
unmeasured factors such as the severity of mental illness
may still impact on the study results. In addition,
although the outcomes investigated by this study have
high positive predictive values, there is likely to be a
small proportion (eg, ∼5%41) of events that are imper-
fectly recorded and may therefore reduce the accuracy
of our results.
The results of statin effectiveness on CVD outcomes
described by this study have focused on data for the full
population with imputed values of covariate data (on
blood pressure, total cholesterol, smoking status, weight
and height) where these measurements were
unobserved at baseline. Individuals who were not pre-
scribed a statin but who had complete baseline data
made up only a small proportion (12%) of total statin
non-users included in the full analysis. It was therefore
important to extend the analysis beyond individuals for
whom complete data were available. We made every
attempt to develop a robust approach towards imputing
missing covariate data (further outlined in supplemen-
tary ﬁles) but acknowledge that our estimates are not a
substitute for fully observed data. In particular, it was not
possible to develop an imputation model that included
high-density lipoprotein cholesterol (HDL-C) because
>90% of data were missing for HDL-C in early time
periods in the study. Lipid proﬁle (including HDL-C
fraction and trigylcerides) is both predictive of CVD
events and associated with SMI, through mechanisms
such as poorer diet, which is associated with a lower
HDL-C fraction.58 Incomplete characterisation of lipid
proﬁle within this study may result in some residual con-
founding, thereby potentially biasing our estimate of the
effectiveness of statin prescribing, probably towards the
null. The high level of similarity between results for the
primary outcome using imputed data relative to com-
plete cases (outlined in online supplementary ﬁle S4)
adds greater certainty to our ﬁndings.
Meaning
The results from this study provide evidence that the
potential impact of statin prescribing on intermediate
outcomes in people with SMI has a magnitude that is
similar to the general population. We identiﬁed statistic-
ally signiﬁcant reductions in total cholesterol (of
1.2 mmol/L up to 2 years, p<0.001), suggesting that
medication adherence in people with SMI is sufﬁcient to
support effective lipid modiﬁcation. Both CVD screening
and statin prescribing should be encouraged as a poten-
tial means of decreasing the mortality gap in SMI.
However, the impact of these interventions should be
further evaluated relative to other interventions—such
as smoking cessation—for primary prevention of CVD.
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